TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Xinchao ZhangShuyan LiJing HeYunjie JinRuonan ZhangWenjing DongMingen LinYajing YangTongguan TianYuefan ZhouYixin XuQun-Ying LeiJing ZhangYang ZhangYanping XuLei LvPublished in: Cancer research (2022)
The identification of TET2-mediated inhibition of HIF signaling and tumor metabolic reprogramming provides insights for new therapeutic strategies for VHL-deficient ccRCC.